REG - Braveheart Inv Group - Investment update – Kirkstall Limited

Braveheart InvestmentAnnouncement

08/09/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230908:nRSH7748La&default-theme=true

RNS Number : 7748L  Braveheart Investment Group plc  08 September 2023

8 September 2023

 

Braveheart Investment Group plc

("Braveheart" or the "Group")

 

 Investment update - Kirkstall Limited

 

Braveheart Investment Group (AIM: BRH), announces an update on Kirkstall
Limited ("Kirkstall" or the "Company"), a company within the Group's
investment portfolio.

 

Kirkstall, in conjunction with the Biomedical Ultrasonics, Biotherapy and
Biopharmaceutical Laboratory within the Institute of Biomedical Engineering at
the University of Oxford, has developed an "organ on a chip" model of an
innovative, milli-fluidic system, human blood-brain barrier which has been
used to map the interaction between the blood-brain barrier and brain cancer.

 

This is the first time a dynamic milli-fluidic model has been developed where
the interactions between the blood-brain barrier and medulloblastoma brain
cancer spheroids have been demonstrated. The model uses the Kirkstall's Quasi
Vivo® platform, a unique milli-fluidic system. This innovation will enable
the observation of the in vitro performance of drugs designed for treating
brain cancer and central nervous system diseases such as Alzheimer's.

 

Braveheart holds a 86.11% equity interest in Kirkstall. In addition, it has
provided unsecured interest free loans to Kirkstall totalling £10,752 as at
31 March 2023.

 

Trevor Brown, CEO of Braveheart Investment Group plc, commented: "It is
exciting to observe how collaboration between Kirkstall and Oxford University
has resulted in an innovative and important application for the Quasi Vivo
platform."

 

For further information:

 

 Braveheart Investment Group plc                                Tel: 01738 587555
 Trevor Brown CEO

 Allenby Capital Limited (Nominated Adviser and Joint Broker)   Tel: 020 3328 5656
 James Reeve / George Payne

 Peterhouse Capital Limited (Joint Broker)                      Tel: 020 7469 0936
 Duncan Vasey / Lucy Williams

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PFUGZGGLVNLGFZM